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Abstract
Background There is growing recognition of hypertension in a significant proportion of children with ADPKD. In this study, we
assessed blood pressure and cardiovascular status in children with ADPKD.
Methods A prospective two-centre observational study of children (< 18 years) with ADPKD was compared against age- and
BMI-matched healthy controls. Children underwent peripheral BP (pBP) measured using an aneroid sphygmomanometer and
auscultation, 24-h ambulatory BPmonitoring (ABPM), non-invasive central BP (cBP) measurement, carotid-femoral pulse wave
velocity (PWVcf) measured using applanation tonometry and measurement of indexed left ventricular mass (LVMI) using
echocardiography. This study received independent ethical approval.
Results Forty-seven children with ADPKD and 49 healthy controls were recruited (median age 11 years vs. 12 years). Children
with ADPKD had significantly higher systolic pBP (mean 112 ± 13.5mmHg vs. 104 ± 11mmHg, p < 0.001), higher systolic cBP
(mean 97 ± 12.8 mmHg vs. 87 ± 9.8 mmHg, p < 0.001) and lower pulse pressure amplification ratio (1.59 ± 0.2 vs. 1.67 ± 0.1,
p = 0.04) compared to healthy children. Thirty-five percent of children with ADPKD showed a lack of appropriate nocturnal
dipping on 24-h ABPM. There was no difference in PWVcf between children with ADPKD and healthy children (mean 5.74 ±
1 m/s vs. 5.57 ± 0.9 m/s, p = 0.46). Those with ADPKD had a significantly higher LVMI (mean 30.4 ± 6.6 g/m2.7 vs. 26.2 ± 6.2 g/
m2.7, p = 0.01).
Conclusions These data highlight the high prevalence of hypertension in children with ADPKD, also demonstrating early
cardiovascular dysfunction with increased LVMI and reduced PP amplification despite preserved PWVcf, when compared with
healthy peers. These early cardiovascular abnormalities are likely to be amenable to antihypertensive therapy, reinforcing the
need for routine screening of children with ADPKD.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD)
was traditionally considered an ‘adult’ disease [1], but
recent evidence from multiple studies has shown a sig-
nificant prevalence of hypertension and other features
suggestive of early cardiac damage during childhood
[2–4]. Despite this, most children at risk of ADPKD
do not receive regular or consistent medical follow-up
[5, 6]. There are still no guidelines recommending rou-
tine diagnostic testing of children with ADPKD; rather
children at risk (by virtue of their family history) can be
monitored and then evaluated if any problems are de-
tected, until direct anti-ADPKD therapies gain approval
in children [7].
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The commonest significant clinical issue in ADPKD
during childhood appears to be hypertension, which we
reported at ~ 20% of affected children in a recent meta-
analysis [4]. Some studies (including the largest single
study published to date) report higher prevalence of hyper-
tension in children with ADPKD, up to 35% [8]. It should
be recognised, however, that many of these studies come
from specialist clinics which make them susceptible to se-
lection bias; current estimates may therefore overestimate
the prevalence of hypertension in this population. It is per-
haps paradoxical that adult studies report median age at
diagnosis of hypertension as 33 years with a very low
number diagnosed before age 20; it is likely these figures
reflect lack of screening in those with ADPKD in the ab-
sence of overt symptoms [9].
The mechanism underlying childhood hypertension in
ADPKD remains unknown, and it precedes the decline in
renal function. However, the strongest evidence exists for pro-
gressive cyst expansion and proliferation affecting regional
perfusion and drainage, leading to activation of the renin-
angiotensin-aldosterone system [10, 11]. This leads to vaso-
constriction with salt and water accumulation. Other potential
mechanisms include endothelial dysfunction, increased vaso-
pressin levels and sympathetic overactivity [10].
Although hypertension in children with ADPKD is now
increasingly recognised, literature on other aspects of their
cardiovascular status remains limited. Increased left ventricu-
lar mass index (LVMI) in children with ADPKD who are
hypertensive has been reported, but interestingly, this study
also found an increased LVMI in those with borderline hyper-
tension [3]. To our knowledge, there have only been two pre-
vious studies considering other measures of vascular health in
children with ADPKD. These reported early vascular disease,
but the studies were small (n = 36 in total), included young
adults above 18 years of age and had only 23 children (64%)
aged 16 or younger across both studies combined [12, 13].
Recent adult evidence highlights markers of vascular
health in predicting adverse cardiovascular outcomes. In par-
ticular, central blood pressure (cBP) appears more closely
linked to cardiovascular risk than peripheral blood pressure
(pBP) [14]. Along with the studies mentioned above [12,
13], cBP has previously been studied in 18 adults (mean age
34 years) with ADPKD and they found evidence of early
arterial pathology in this population [15].
The primary aim of this study was to assess vascular
health in children with ADPKD by measuring pBP and
cBP, carotid-femoral pulse wave velocity (PWVcf) and
left ventricular mass index (LVMI) and by comparing
these to age- and BMI-matched healthy controls.
Secondary aims included comparing pBP values with 24-
h ambulatory BP monitoring (ABPM) in those with
ADPKD, as well as assessment of microalbuminuria and
estimated glomerular filtration rate.
Materials and methods
Participants
This was a prospective two-centre observational study con-
ducted across two large paediatric nephrology units in
London, UK: Evelina London Children’s Hospital (ELCH)
and Great Ormond Street Hospital for Children. Children
and adolescents (< 18 years) were consecutively recruited
from paediatric nephrology clinics and a dedicated polycystic
kidney disease clinic at ELCH. Inclusion criteria were a con-
firmed diagnosis of ADPKD (confirmed through ultrasonog-
raphy using the Modified Ravine criteria, or in those aged
under 15 years, a finding of renal cysts in the context of a
family history of ADPKD—criteria used in the recent large
pan-European study) [8]. Exclusion criteria were those chil-
dren with unilateral cysts in the absence of a family history of
ADPKD. We also excluded children aged under 3, as they
were felt to be unlikely to tolerate detailed vascular assess-
ments. Comparisons in this study were made against a group
of age- and BMI-matched healthy controls, who were recruit-
ed from the local population. Formal ethical approval for this
study was granted following external ethical review by the
Hampstead Research Ethics Committee at Royal Free
Hospital, London (REC number 15/LO/1100). All par-
ticipants in this study (or their parents) gave written
informed consent, plus children gave their assent where
age-appropriate.
Baseline data was collected for all those studied with
ADPKD, including demographics, latest renal ultrasound
findings, method of confirmation of ADPKD and presence
of a family history. We also collected data on current or his-
torical symptoms and signs related to ADPKD, including
those with pre-existing hypertension (defined as a systolic or
diastolic BP above the 95th percentile for age, sex and height
or the use of antihypertensive medication). We used defini-
tions as per the 2016 European Society of Hypertension
Guidelines [16]. In those with ADPKD, we recorded the ran-
dom urine albumin to creatinine ratio; microalbuminuria was
defined as a urine albumin to creatinine ratio above the normal
range (0–2.4 g/mol). The urine was collected in a clinic setting
and was not always the first morning urine. We calculated
their estimated glomerular filtration rate (eGFR) using the
New Modified Schwartz formula from 2009 [17, 18].
Demographic data was collected for healthy controls, as well
as eGFR if blood tests were done, but formal laboratory urine
testing was not performed.
Blood pressure measurement
Peripheral systolic and diastolic BP was measured in partici-
pants seated for 5 min in a quiet environment. Trained ob-
servers measured peripheral BP at the brachial artery thrice
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by auscultation using a calibrated aneroid sphygmomanome-
ter, and the mean was used for further analyses. Z-scores for
pBP were calculated according to the Fourth Report [19].
Radial artery applanation tonometry was performed next
on the right wrist of each subject by lightly applying a high-
fidelity micromanometer (SPC-301; Millar Instruments,
Houston, TX) to the radial artery. All readings were processed
by the SphygmoCor device (AtCor Medical, West Ryde, New
South Wales, Australia), which gave an estimate of cBP
through calibration with pBP. Only those radial waveforms
meeting the inbuilt quality control criteria of the
SphygmoCor device were accepted. Three estimates of cBP
were taken, and the mean of these readings was recorded.
Pulse pressure (PP) amplification was assessed as the ratio
of peripheral to central pulse pressure (brachial to aortic PP).
Twenty-four-hour ABPM was performed in children
with ADPKD using the Spacelabs Healthcare 90217 re-
corder (OSI Systems, Hawthorne, California) and an ap-
propriately sized cuff; children too young to tolerate the
ABPM were excluded. Mean 24-h, daytime and noctur-
nal BP values were recorded. An ABPM study was
excluded if (1) there was 2 h of interrupted recordings
or (2) the duration of recording was inadequate (i.e.
20 h in total, 12 h continuously or did not include
night-time measurements) [20]. Twenty-four-hour
ABPM data was compared to clinic pBP data as above.
Cardiovascular assessments
In addition to cBP measurement and pulse pressure amplifi-
cation as above, further assessment of vascular health was
undertaken with carotid-femoral pulse wave velocity
(PWVcf) measurement. Arterial waveforms were obtained
from the carotid and femoral arteries with the patient in the
supine position; these were processed using the SphygmoCor
device, and PWVcf was calculated with simultaneous 3-lead
ECG monitoring. PWVcf was measured three times in suc-
cession, and the mean value was recorded. PWVcf Z-scores
were calculated using the LMS method with data from Reusz
et al. [21].
Indexed left ventricular mass (LVMI) was measured using
standard two-dimensional m-mode echocardiography. All
echocardiograms were performed by a single trained operator
who was blinded to the diagnosis, blood pressure and other
vascular data. Left ventricular hypertrophy was defined as
LVMI > 51 g/m2.7.
Statistical analyses
Summary statistics are presented as means for continuous data
and proportions for categorical data. Comparisons between the
two groups in this study were tested using the dependent or
independent sample t test for continuous data if the data were
normally distributed (checked using the Shapiro-Wilk test).
Where data were not normally distributed, the non-parametric
Mann-Whitney U test was used for independent samples. The
chi-squared test was used for categorical data. Statistical anal-
yses were performed using SPSS version 22 (SPSS Inc.,
Chicago, Illinois). All tests were two-tailed, and a p value <
0.05 was taken to represent a statistically significant result.
Results
Forty-seven children with ADPKD and 49 healthy controls
were recruited with groups well matched for age and BMI
(Table 1). Themedian age of thosewithADPKDwas 11 years,
and two children were under the age of 5 years at the time of
the study. There was a significantly lower eGFR in the
ADPKD group when compared with healthy controls, but
most were normal and only three children (6%) with
ADPKD had an eGFR < 60 mL/min/1.73 m2.
Table 2 shows the clinical characteristics of the ADPKD
group; in total, 10 children (21%) met the criteria for hyper-
tension in this study. Interestingly, 5 children (11%) were pre-
natally diagnosed or suspected to have ADPKD; one of these
Table 1 Baseline characteristics
ADPKD (n = 47) Healthy (n = 49) p value
Median age (range), years 11 (3–17) 12 (6–17) 0.91
Male 26 (55%) 19 (39%) 0.10
Median weight (range), kg 42 (16–120) 48 (22–107) 0.25
Median height (range), cm 152 (103–189) 153 (125–186) 0.62
Median BMI (range), kg/m2 18 (15–34) 20 (14–38) 0.17
Median eGFR (range), mL/min/1.73 m2 86 (49–147) 103 (71–120) 0.004
Missing data: 4 children in the ADPKD group and 15 children in the healthy control group did not have blood
tests done, and therefore, eGFR was not estimated
BMI body mass index, eGFR estimated glomerular filtration rate
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children was known to have inherited a PKD1 mutation from
one parent and a hypomorphic mutation in the other. Twelve
children with ADPKD (26%) in this study had history of re-
current urinary tract infections (UTIs). Eighteen children with
ADPKD (out of 43 where urine testing was completed, 42%)
had microalbuminuria, with the mean albumin to creatinine
ratio on a study level only slightly higher than the upper limit
of the normal range.
Blood pressure
Children with ADPKD had significantly higher peripheral
and central blood pressure levels (Table 3). We found a
significantly lower PP amplification ratio in the ADPKD
group, compared to the healthy controls, suggesting that
there is a degree of arterial stiffening in this population.
There was a statistically significant positive correlation be-
tween the PP amplification ratio and age (rs 0.41, p = 0.01)
and a negative correlation with eGFR (rs − 0.47, p = 0.005)
Spearman rank correlation coefficient. Figure 1 shows the
pSBP Z-score plotted against age in 47 children with
ADPKD, showing a tendency towards a higher blood pres-
sure Z-score with increasing years, but this was not statis-
tically significant (R2 = 0.0519, p = 0.12). This figure high-
lights those who were on anti-hypertensive medication at
the time of the study and those with a reduced eGFR.
Twenty-four-hour ABPM data was available for 37 chil-
dren with ADPKD (10 children had inadequate ABPM,
were unable to tolerate or were too young to have
ABPM). ABPM results are in Table 3. Thirteen of 37 chil-
dren (35%) showed a lack of appropriate nocturnal dipping
on 24-h ABPM (< 10% dip in SBP).
Table 2 Clinical characteristics in
47 children with ADPKD Blood pressure On antihypertensive treatment 8 (17%)
Hypertensive but not on treatment 2 (4%)
Clinical characteristics and symptoms Family history of ADPKD 43 (91%)
Antenatally diagnosed/suspected 5 (11%)
Abdominal/back pain 5 (11%)
Recurrent UTIs 12 (26%)
Assessment of proteinuria Raised random albumin to creatinine ratio 18 (42%)
Mean albumin to creatinine ratio (g/mol) 4.6
Missing data: 4 children in the ADPKD group did not have urine tests
UTI urinary tract infection
Table 3 Blood pressure and
cardiovascular assessments ADPKD (n = 47) Healthy (n = 49) p value
Mean (SD) pSBP (mmHg) 112 (± 13.5) 104 (± 11) < 0.001
Mean (SD) pSBP Z-score 0.49 (± 1) − 0.33 (± 0.8) < 0.001
Mean (SD) pDBP (mmHg) 65 (± 12.1) 60 (± 12.8) 0.04
Mean (SD) pDBP Z-score 0.27 (± 1) − 0.26 (± 1.1) 0.01
Mean (SD) cSBP (mmHg) 97 (± 12.8) 87 (± 9.8) < 0.001
Mean (SD) cDBP (mmHg) 67 (± 12.1) 61 (± 12.2) 0.04
Mean (SD) peripheral PP (mmHg) 47 (± 9.7) 43 (± 12.5) 0.15
Mean (SD) central PP (mmHg) 30 (± 5.3) 26 (± 7.7) 0.006
Mean (SD) ratio peripheral/central PP 1.59 (± 0.2) 1.67 (± 0.1) 0.04
Mean (SD) PWVcf (m/s) 5.74 (± 1) 5.57 (± 0.9) 0.46
Mean (SD) PWVcf Z-score 1.21 (± 1) 0.78 (± 0.9) 0.07
Mean (SD) echo LVMI (g/m2.7) 30.4 (± 6.6) 26.2 (± 6.2) 0.01
Mean 24-h ABPM blood pressure 113/68
Mean daytime ABPM blood pressure 117/72
Mean nocturnal ABPM blood pressure 104/59
pSBP peripheral systolic blood pressure, pDBP peripheral diastolic blood pressure, cSBP central systolic blood
pressure, cDBP central diastolic blood pressure, PP pulse pressure, PWVcf carotid-femoral pulse wave velocity,
LVMI left ventricular mass index
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Cardiovascular assessments
We found no significant difference in PWVcf between the
children with ADPKD and the healthy children [mean 5.74
± 1 m/s vs. 5.57 ± 0.9 m/s, p = 0.46, mean Z-score 1.21 vs.
0.78, p = 0.07]. There was a significantly higher LVMI in
those with ADPKD compared to healthy children [mean
30.4 ± 6.6 g/m2.7 vs. 26.2 ± 6.2 g/m2.7, p = 0.01]. Although
this was demonstrated on a study level, no children met the
definition for left ventricular hypertrophy.
Discussion
This is the first study to systematically assess blood pressure
and cardiovascular status in a large population of children with
ADPKD and compare with age-matched healthy controls. We
have identified that those with ADPKD have higher mean pe-
ripheral and central blood pressures, compared to healthy chil-
dren. Twenty-one percent of children in this study were hyper-
tensive or on anti-hypertensive medication, which is consistent
with ranges in the published literature [4]. That 8 children in our
study were on anti-hypertensive medication suggests that the
truemean BP valuesmay be even greater in the ADPKD group,
had they not been on anti-hypertensives at the time of the study.
We also found that children with ADPKD had significantly
higher indexed LV mass, compared to healthy controls.
The results of our study are in agreement with other paedi-
atric work reporting an increased central blood pressure in
children and young adults with ADPKD [12]. Central blood
pressure characteristics have been reported in one adult study
of 18 individuals with ADPKD; this study found higher cen-
tral systolic and diastolic BP in young adults with ADPKD
[15]. As well as observing a raised cBP, we have also found a
lower PP amplification ratio in children with ADPKD. A low-
er PP amplification ratio may be an important marker of vas-
cular stiffness and future cardiovascular risk [22]. A conse-
quence of its resultant haemodynamic effect would be that for
a given pPP, an individual with lower PP amplification will
have a higher cPP and therefore a higher left ventricular
afterload. Our study may provide evidence of arterial stiffen-
ing in young children with ADPKD at a median age of
11 years, but data on the relationship between these cardiovas-
cular assessments and arterial stiffening are lacking in the
paediatric population. We found a significant positive correla-
tion between the PP amplification ratio and age and a negative
correlation between PP amplification ratio and eGFR. Both
findings are difficult to explain. Our study was not designed
to investigate this, so whilst it is interesting to note, we cannot
draw conclusions on the basis of this.
There have only been two previous similar studies of vas-
cular health including children with ADPKD. Nowak et al.
considered vascular health in children and young adults with
ADPKD, but this study only included 15 individuals with
ADPKD, and they had a median age of 21 years with 7 par-
ticipants being 16 years old or younger. In this study, they
found a raised PWVcf in those with ADPKD, compared to
healthy controls [12]. Karava et al. studied 21 children and
young adults aged 7–19 years and found an increased PWV in
4 (19%) children, but they did not have a healthy control
comparison group [13]. Our study used the same methods
















Age vs pSBP Z-score in 47 children with ADPKD
Fig. 1 Graph showing peripheral
systolic blood pressure Z-score
against age in 47 children with
ADPKD. R2 = 0.0519 (p = 0.12).
Marker coding: triangle, children
with ADPKD who were on anti-
hypertensive medication at the
time of the study; circle, children
with ADPKD who were both on
anti-hypertensive medication at
the time of the study and had an
eGFR < 60 mL/min/1.73 m2;
square, child with ADPKD who
had an eGFR < 60 mL/min/
1.73 m2; diamond, all other chil-
dren with ADPKD in the study
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and found no significant difference in PWVcf between chil-
dren with ADPKD and healthy controls.
Although we did find some evidence of arterial stiffening
in those with ADPKD through a lower PP amplification ratio,
the lack of a significant difference in PWVcfmay be due to the
younger mean age of children in our study, compared to the
study by Nowak et al. [12]. However, there have been other
studies in young adults with ADPKD where no difference in
PWVcf has been found [15]. The reasons for these conflicting
findings are not clear, but these are likely related to different
techniques for measuring both BP and PWV [23]. It may also
be that significant large arterial stiffening occurs variably dur-
ing childhood and young adulthood, and therefore, wide-
spread vascular changes are not seen until later adult life.
Our study also found that 35% of children with ADPKD had
a loss of nocturnal dipping on 24-h ABPM; this is relatively
consistent (although slightly lower) compared to a large re-
cently published study by Massella et al. [8].
Other important findings in our study include further evi-
dence of target organ damage in children with ADPKD, poten-
tially as a result of hypertension or the disease itself.We found a
higher mean LVMI in those with ADPKD, compared to healthy
children. Whilst this finding is not novel [3], it adds to the
evidence base suggesting that early cardiovascular changes
are seen in children with ADPKD. We also found that 42% of
patients with ADPKD had evidence of microalbuminuria, with
9% having an ACR above 10 g/mol. We report higher levels of
microalbuminuria than some other studies, but this may be due
to our urine samples being collected in the clinic randomly;
therefore, there may be an orthostatic effect in some children.
The mechanisms of proteinuria in early ADPKD are not yet
fully understood, but theories suggest that glomerular
hyperfiltration and abnormal endocytosis in tubules may ac-
count for this in part. Microalbuminuria in children with
ADPKD is not consistently correlated to disease severity [24].
Nevertheless, our finding is important because it provides fur-
ther rationale for initial treatment of hypertension with the
renin-angiotensin-aldosterone system (RAAS) blockade, in
view of the well-established antiproteinuric effects.
Strengths of our study include the consecutive recruitment of
a relatively large population of children with ADPKD. The con-
secutive recruitment may also explain why the prevalence of
hypertension in our study is lower than some other studies which
may have suffered from selection bias. We also used a strict
definition for hypertension as per current European guidelines
[16]. Additional strengths include a well-matched group of
healthy controls. Many previous studies of children with
ADPKD have also included young adults, making it difficult to
separate out the findings relevant to younger children and ado-
lescents. Our study included only those aged less than 18 years,
so the results can be truly applicable to paediatric patients.
Our study has some limitations that need to be acknowl-
edged. Firstly, like many studies in paediatric ADPKD, our
study is likely to suffer from some tertiary centre bias.
Therefore, we may to some extent over-estimate the preva-
lence of hypertension and proteinuria in this cohort. We also
acknowledge that urine samples collected in a clinic setting
may also over-estimatemicroalbuminuria due to an orthostatic
effect, although we would not expect such a significant num-
ber if it was purely due to this. Whilst our study population
includes some children on anti-hypertensive therapy or with
reduced eGFR which can add complexity to the interpretation
of cardiovascular assessments, these individuals do not signif-
icantly skew the results and they can be seen clearly in Fig. 1
where their impact on pSBP is depicted.
The proposed mechanisms of hypertension in ADPKD have
been described previously in our introduction. Given that most
children with ADPKD have a low cyst burden, it is likely that
mechanisms other than cyst proliferation and expansion also
contribute to the development of hypertension in this population.
Previous studies have shown that childrenwith a higher cyst load
have a higher risk of hypertension [25]. However, given that
activation of the RAAS is still likely to be a major contributor
to hypertension in children with ADPKD, we support the use of
ACE inhibitors and angiotensin receptor blockers as the first-line
anti-hypertensive agent in this population.
In conclusion, we have found that children with
ADPKD have higher blood pressure levels and evidence
of early cardiovascular abnormalities, compared to
healthy children. There is also a high prevalence of
microalbuminuria in this population. Further research is
required to understand the mechanisms of elevated BP in
children with ADPKD and its influence on the evolution
of target organ damage. We propose a large population-
based study of children at risk of ADPKD to determine
the prevalence of hypertension and cardiovascular dis-
ease in this cohort, as well as performing cardiac and
renal MRI to determine further markers of cardiovascular
status and link these with cyst burden and renal size.
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